Please login to the form below

Not currently logged in
Email:
Password:

Pfizer may counter Daiichi's bid for Ranbaxy

Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a Business Standard report
Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a report in the Business Standard newspaper.

Ranbaxy, founded by the Singh family, has agreed a deal with Japan's Daiichi Sankyo, worth up to $4.6bn to take control of the company. However, it is rumoured that Pfizer, which held talks with Ranbaxy a year ago, may be about to make a counter bid.

According to the newspaper, a Ranbaxy spokesman said: "We have a binding contract with Daiichi. It is a final contract."

Pfizer has lost out to Ranbaxy in several international battles over the patent rights to Lipitor, its cholesterol drug. In most countries the patent will start expiring in 2011.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics